Clinical and Outcome Data for Patients in the RAFF4 Trial Comparing Vernakalant and Procainamide for Cardioversion of Acute Atrial Fibrillation

This dataset originates from the RAFF4 randomized clinical trial, which compared the effectiveness of vernakalant and procainamide in achieving rapid cardioversion in patients presenting with acute atrial fibrillation (AF). The trial was conducted between June 2021 and August 2024 across the emergency departments of 12 tertiary care hospitals in Canada, enrolling 350 adult patients. The dataset includes anonymized patient-level data on clinical characteristics, treatment assignments, conversion outcomes, and time to conversion. Variables include demographic information (age, sex), atrial fibrillation episode history, comorbidities (e.g., heart failure), treatment group assignment (vernakalant or procainamide), hospital site, disposition outcome, conversion method (drug, electrical, spontaneous, or unsuccessful), and time to cardioversion in minutes. The dataset was generated to support the analysis and findings reported in the BMJ publication: "Vernakalant versus Procainamide for Rapid Cardioversion of Patients with Acute Atrial Fibrillation (RAFF4): A Randomized Clinical Trial" (Stiell et al., 2025).